RU2013126403A - Кристаллические формы алкоксиимидазол-1-илметилбифенилкарбоновых кислот - Google Patents

Кристаллические формы алкоксиимидазол-1-илметилбифенилкарбоновых кислот Download PDF

Info

Publication number
RU2013126403A
RU2013126403A RU2013126403/04A RU2013126403A RU2013126403A RU 2013126403 A RU2013126403 A RU 2013126403A RU 2013126403/04 A RU2013126403/04 A RU 2013126403/04A RU 2013126403 A RU2013126403 A RU 2013126403A RU 2013126403 A RU2013126403 A RU 2013126403A
Authority
RU
Russia
Prior art keywords
crystalline
hemidisilate
salt
salt according
powder
Prior art date
Application number
RU2013126403/04A
Other languages
English (en)
Russian (ru)
Inventor
Пол Р. Фазери
Венкат Р. ТАЛЛАДИ
Original Assignee
ТЕРЕВАНС БАЙОФАРМА Р энд Д ИП,ЛЛС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТЕРЕВАНС БАЙОФАРМА Р энд Д ИП,ЛЛС filed Critical ТЕРЕВАНС БАЙОФАРМА Р энд Д ИП,ЛЛС
Publication of RU2013126403A publication Critical patent/RU2013126403A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2013126403/04A 2010-11-10 2011-11-09 Кристаллические формы алкоксиимидазол-1-илметилбифенилкарбоновых кислот RU2013126403A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41201110P 2010-11-10 2010-11-10
US61/412,011 2010-11-10
PCT/US2011/059895 WO2012064807A1 (en) 2010-11-10 2011-11-09 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Publications (1)

Publication Number Publication Date
RU2013126403A true RU2013126403A (ru) 2014-12-20

Family

ID=45003086

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013126403/04A RU2013126403A (ru) 2010-11-10 2011-11-09 Кристаллические формы алкоксиимидазол-1-илметилбифенилкарбоновых кислот

Country Status (19)

Country Link
US (3) US8362060B2 (cg-RX-API-DMAC10.html)
EP (1) EP2638017B1 (cg-RX-API-DMAC10.html)
JP (2) JP2013542258A (cg-RX-API-DMAC10.html)
KR (1) KR20130130730A (cg-RX-API-DMAC10.html)
CN (1) CN103189362B (cg-RX-API-DMAC10.html)
AR (1) AR083828A1 (cg-RX-API-DMAC10.html)
AU (1) AU2011326622B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013011715A2 (cg-RX-API-DMAC10.html)
CA (1) CA2812598A1 (cg-RX-API-DMAC10.html)
CO (1) CO6741224A2 (cg-RX-API-DMAC10.html)
ES (1) ES2567721T3 (cg-RX-API-DMAC10.html)
IL (1) IL225303A0 (cg-RX-API-DMAC10.html)
MX (1) MX2013005165A (cg-RX-API-DMAC10.html)
NZ (1) NZ609804A (cg-RX-API-DMAC10.html)
PH (1) PH12013500945A1 (cg-RX-API-DMAC10.html)
RU (1) RU2013126403A (cg-RX-API-DMAC10.html)
SG (1) SG189448A1 (cg-RX-API-DMAC10.html)
TW (1) TW201300366A (cg-RX-API-DMAC10.html)
WO (1) WO2012064807A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法
CN117769540A (zh) * 2021-05-11 2024-03-26 亚士德制药公司 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
TWI545114B (zh) 2009-09-29 2016-08-11 施萬生物製藥研發Ip有限責任公司 製備聯苯基咪唑化合物之方法
US8399501B2 (en) * 2010-03-04 2013-03-19 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof

Also Published As

Publication number Publication date
US20130267573A1 (en) 2013-10-10
CN103189362B (zh) 2015-03-11
IL225303A0 (en) 2013-06-27
US8362060B2 (en) 2013-01-29
JP2013542258A (ja) 2013-11-21
CA2812598A1 (en) 2012-05-18
US9249105B2 (en) 2016-02-02
BR112013011715A2 (pt) 2017-10-31
US8802709B2 (en) 2014-08-12
SG189448A1 (en) 2013-05-31
HK1187919A1 (zh) 2014-04-17
US20150133518A1 (en) 2015-05-14
AU2011326622B2 (en) 2014-12-18
JP2016028061A (ja) 2016-02-25
WO2012064807A1 (en) 2012-05-18
EP2638017B1 (en) 2016-01-27
EP2638017A1 (en) 2013-09-18
NZ609804A (en) 2015-02-27
CO6741224A2 (es) 2013-08-30
ES2567721T3 (es) 2016-04-26
AR083828A1 (es) 2013-03-27
PH12013500945A1 (en) 2013-07-08
MX2013005165A (es) 2013-07-05
US20120115920A1 (en) 2012-05-10
TW201300366A (zh) 2013-01-01
AU2011326622A1 (en) 2013-04-04
CN103189362A (zh) 2013-07-03
KR20130130730A (ko) 2013-12-02

Similar Documents

Publication Publication Date Title
CN106795099B (zh) 用于治疗高血压和心血管疾病的前药和组合物
RU2580320C2 (ru) Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
AU722360B2 (en) Integrin antagonists
US5684028A (en) Sulphorous derivatives of imidazole, their preparation process, the new intermediates obtained, their use as medicaments and the pharmaceutical compositions
JP5595402B2 (ja) アンドロゲン受容体モジュレーターとしての新規イミダゾリジン化合物
JP2015524476A5 (cg-RX-API-DMAC10.html)
RU2015110122A (ru) Производные имидазолина, способы их получения и их применение в медицине
RU2014151565A (ru) Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
AU6023198A (en) Integrin antagonists
FI2744810T4 (fi) Tenofoviirialafenamidihemifumaraatti
TW201004616A (en) Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
WO2006038594A1 (ja) N型カルシウムチャネル阻害薬
JP2012532872A5 (cg-RX-API-DMAC10.html)
JP2019537584A (ja) Lsd1阻害剤およびその医学的使用
JP2000516197A (ja) インテグリンレセプターアンタゴニスト
AU2008233553A1 (en) Indole derivative having cPLA2 inhibitory activity, use of the same and method for producing the same
RU2011117635A (ru) Кристаллическая форма алкоксиимидазол-1-илметилбифенилкарбоновой кислоты
JP2012526769A5 (cg-RX-API-DMAC10.html)
CN104039793B (zh) 二氢吡咯并[1,2‑c]咪唑基醛固酮合成酶或芳香酶抑制剂的形式及盐
JP2010522168A (ja) 鉱質コルチコイドレセプターモジュレータ
RU2013125756A (ru) Твердые формы (s)-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропановой кислоты
JP2013501072A5 (cg-RX-API-DMAC10.html)
JP2013542258A5 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20151215